overview: Hormone replacement therapy (HRT) use was associated with increased cognitive performance, memory, and brain volume in women with APOE4 gene variants associated with Alzheimer’s disease.
sauce: University of East Anglia
Hormone replacement therapy (HRT) may help prevent Alzheimer’s disease in women who are at risk of developing Alzheimer’s disease, according to a University of East Anglia study.
This study shows that HRT use is associated with better memory, cognition, and larger brain volume later in life in women with the APOE4 gene, the strongest risk factor gene for Alzheimer’s disease. I’m here.
The research team found that HRT was most effective when introduced early in the menopause, around menopause.
Professor Anne-Marie Minihane, UEA’s Norwich Medical School, and Director of the UEA’s Norwich Institute for Healthy Aging, co-led the study with Professor Craig Ritchie, University of Edinburgh.
Professor Minihane said:
“In addition to living longer, the reason for the higher prevalence in women is believed to be related to the effects of menopause and the greater influence of genetic risk factors for APOE4 in women.
“We wanted to see if HRT could prevent cognitive decline in at-risk APOE4 carriers.”
The research team examined data from 1,178 women participating in the European Alzheimer’s Disease Prevention Initiative.
The project spanned 10 countries and tracked participants’ brains from “healthy” to some dementia diagnoses. Participants were included if they were over 50 years old and without dementia.
The research team studied the results to analyze the effects of HRT on women with pre-existing medical conditions. APOE4 Genotype.
Dr. Rasha Saleh, also from Norwich Medical School, UEA, said: This association was particularly pronounced when he was introduced to HRT early during the transition to menopause, known as perimenopause.
“This is very important as drug options for Alzheimer’s disease have been very limited for 20 years and new treatments are urgently needed.
“The effects of HRT in this observational study, if confirmed in intervention trials, would correspond to several years younger brain age.”
Professor Anne Marie Minihane said: Although we did not examine cases of dementia, decline in cognitive ability and brain volume predicts future dementia risk.
Professor Michael Hornberger of UEA’s Norwich Medical School said:
“The next step in this research is to conduct an intervention trial to see the effects of starting HRT early on cognition and brain health. It is also important to analyze the
Professor Craig Ritchie of the University of Edinburgh said: “This important finding from the EPAD cohort shows that many assumptions about early Alzheimer’s disease and its treatment need to be challenged, especially when considering brain health in women. I am emphasizing.
See also
“The effects of MRI on both cognition and brain changes support the idea that HRT has tangible benefits. These initial findings need to be replicated in other populations.”
About this genetics and Alzheimer’s research news
author: press office
sauce: University of East Anglia
contact: Press Office – University of East Anglia
image: image is public domain
Original research: open access.
“Hormone Replacement Therapy is Associated with Improved Cognitive Performance and Increased Brain Volume in APOE4 Women at Risk: Results from the European Alzheimer’s Disease Prevention (EPAD) Cohort” Anne-Marie Minihane and others Alzheimer’s disease research and treatment
overview
Hormone Replacement Therapy is Associated with Improved Cognitive Performance and Increased Brain Volume in APOE4 Women at Risk: Results from the European Alzheimer’s Disease Prevention (EPAD) Cohort
Background
The risk of dementia is higher in women than in men. The metabolic consequences of menopausal estrogen decline accelerate neuropathology in women. The use of hormone replacement therapy (HRT) in preventing cognitive decline has shown conflicting results.Here, we investigate the regulatory role of appointment Genotype and age at HRT initiation for heterogeneity in cognitive response to HRT.
method
In this analysis, the European Alzheimer’s disease prevention (EPAD) cohort (total n= 1906, women = 1178, 61.8%). Independent and interactive effects were tested using covariate analysis (ANCOVA) models. appointment Genotypes and HRT on selected cognitive tests such as MMSE, RBANS, dot counting, Four Mountain Test (FMT), and Supermarket Trolley Test (SMT), along with volume of the medial temporal lobe (MTL) region by MRI. . Multiple linear regression models were used to examine the effect of HRT initiation age. APOE4 Carrier status for these cognitive and MRI outcomes.
result
APOE4 HRT users had the highest RBANS delayed memory index scores (P-appointment*HRT interaction = 0.009) compared APOE4 to non-users and non-usersAPOE4 Carriers with 6-10% greater volume of entorhinal (left) and amygdala (left and right) (P.-interaction=0.002, 0.003, and 0.005 respectively). Early introductions of HRT were based on greater rights (standardized β= −0.555, p=0.035) and left hippocampal volume (standardized β= −0.577, p=0.028) only APOE4 career.
Conclusion
Introduction of HRT is associated with improved delayed memory and increased entorhinal and amygdala volumes. APOE4 career only. This may represent an effective targeted strategy to mitigate the higher lifetime risk of AD in this large at-risk population subgroup.Validation of findings in fit-for-purpose RCTs appointment Genotypes are required to establish causality.
